ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1599

Single-Cell RNA Sequencing Reveals Cellular Drivers of UV-mediated Skin Injury in Cutaneous Lupus

Mitra Maz1, Feiyang Ma2, Mehrnaz Gharaee-Kermani2, Amanda Victory2, Amy Hurst2, Johann E. Gudjonsson2 and J. Michelle Kahlenberg2, 1University of Michigan Medical School, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI

Meeting: ACR Convergence 2023

Keywords: immunology, skin, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: Abstracts: SLE – Etiology & Pathogenesis

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: Ultraviolet light (UV) is a known trigger of cutaneous lupus erythematosus (CLE) flares in systemic lupus erythematosus (SLE) patients, yet cell populations and mechanisms driving UV-induced skin inflammation are poorly understood. In this study, we use single-cell RNA sequencing of skin from healthy control (HC) and SLE patients with a history CLE to identify differences in SLE UV responses that serve as novel mediators of UV injury.

Methods: Seven HC and eight SLE patients were recruited. Biopsies were taken from the upper thigh 24 hours after treatment with 1x minimal erythema dose or from unexposed skin. Cells were processed via 10x pipelines, RNA was sequenced with an average of 10,000 reads per cell, and DEGs were analyzed and compared between HC and SLE patients.

Results: Globally, an increase in type I IFN regulated gene expression was seen in SLE >HC across all cell populations after UV exposure. In the epidermis, UV exposure led to differential gene expression in basal keratinocytes (KCs) where stress responses such as S100 proteins were noted in HC, while chemokines and IFN responses were noted in SLE KC, particularly in spinous and basal inflammatory KCs. Subclustering of fibroblast (FB) populations revealed two subpopulations that increase in proportion following UV exposure in both SLE and HC, identified as IFN-FBs and IL6+ FBs. CellphoneDB analysis revealed significant crosstalk between basal and spinous inflammatory KCs and IFN- and IL6+- FBs in SLE skin, suggesting that basal and spinous inflammatory KCs represent critical mediators of UV signal between the epidermis and dermis in lupus. Analysis of the myeloid compartment did not support an influx of pDCs into the skin at our selected timepoint. However, recruitment of myeloid dendritic cells (moDCs) was robust in both SLE and HC skin. Compared with HC skin, moDCs from SLE patients engaged in greater crosstalk with IL-6- and IFN-fibroblasts through CXCL12, a myeloid chemoattractant. Additionally, lupus moDCs engaged in crosstalk with TREM2+ macrophages, a lupus-specific skin resident population, through chemoattractant proteins.

Conclusion: We thus propose that in SLE skin, UV light induces unique inflammatory keratinocyte responses that educate fibroblasts and resident myeloid cells to recruit inflammatory myeloid dendritic cells, which may contribute to inflammatory cytokine production and downstream adaptive immune cell activation in SLE. Targeting of these pathways may be beneficial for prevention of photosensitive responses.


Disclosures: M. Maz: None; F. Ma: None; M. Gharaee-Kermani: Rome Therapeutics, 5; A. Victory: None; A. Hurst: None; J. Gudjonsson: Abbvie, 2, 5, Almirall, 2, 5, AnaptysBio, 2, Boehringer Ingelheim, 2, Celgene/BMS, 2, 5, Eli Lilly, 2, 5, Galderma, 2, Janssen, 2, 5, Kyowa Kirin, 5, MiRagen, 2, Novartis, 2, Prometheus Biosciences, 5, Sanofi, 2, SunPharma, 5, TimberPharma, 5; J. Kahlenberg: AstraZeneca, 1, Bristol-Myers Squibb(BMS), 2, 5, EMD Serano, 2, exo therapeutics, 2, Gilead, 2, GlaxoSmithKlein(GSK), 1, horizon Therapeutics, 2, Janssen, 5, Pfizer, 2, ROME Therapeutics, 2, 5, Rome Therapeutics, 5, Ventus Therapeutics, 2, 5.

To cite this abstract in AMA style:

Maz M, Ma F, Gharaee-Kermani M, Victory A, Hurst A, Gudjonsson J, Kahlenberg J. Single-Cell RNA Sequencing Reveals Cellular Drivers of UV-mediated Skin Injury in Cutaneous Lupus [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/single-cell-rna-sequencing-reveals-cellular-drivers-of-uv-mediated-skin-injury-in-cutaneous-lupus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/single-cell-rna-sequencing-reveals-cellular-drivers-of-uv-mediated-skin-injury-in-cutaneous-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology